The estimated Net Worth of Kathryn O'driscoll is at least $568 Mille dollars as of 15 March 2021. Ms driscoll owns over 837 units of Zymeworks BC Inc stock worth over $70,664 and over the last 5 years she sold ZYME stock worth over $0. In addition, she makes $497,219 as Chief People Officer at Zymeworks BC Inc.
Ms has made over 4 trades of the Zymeworks BC Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she exercised 837 units of ZYME stock worth $28,659 on 15 March 2021.
The largest trade she's ever made was exercising 2,920 units of Zymeworks BC Inc stock on 18 November 2020 worth over $99,981. On average, Ms trades about 1,028 units every 17 days since 2019. As of 15 March 2021 she still owns at least 5,840 units of Zymeworks BC Inc stock.
You can see the complete history of Ms driscoll stock trades at the bottom of the page.
Kathryn O'Driscoll is the Chief People Officer at Zymeworks BC Inc.
As the Chief People Officer of Zymeworks BC Inc, the total compensation of Ms Driscoll at Zymeworks BC Inc is $497,219. There are 3 executives at Zymeworks BC Inc getting paid more, with Dr. Ali Tehrani having the highest compensation of $877,656.
Ms Driscoll is 57, she's been the Chief People Officer of Zymeworks BC Inc since . There are 3 older and 3 younger executives at Zymeworks BC Inc. The oldest executive at Zymeworks BC Inc is Dr. Jennifer Kaufman-Shaw L.L.B., LLB, Ph.D., 71, who is the VP of Intellectual Property.
Kathryn's mailing address filed with the SEC is C/O ZYMEWORKS INC., 1385 WEST 8TH AVENUE, SUITE 540, VANCOUVER, A1, V6H 3V9.
Over the last 6 years, insiders at Zymeworks BC Inc have traded over $15,586,802 worth of Zymeworks BC Inc stock and bought 5,881,975 units worth $49,789,204 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Capital, Llc Eco R1 e Group, Llc Green Jeremy Red.... On average, Zymeworks BC Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,629,555. The most recent stock trade was executed by Kenneth Galbraith on 5 January 2024, trading 47,666 units of ZYME stock currently worth $576,759.
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.
Zymeworks BC Inc executives and other stock owners filed with the SEC include: